RBC Capital raised the firm’s price target on ResMed to $200 from $187 and keeps a Sector Perform rating on the shares. The company delivered a strong Q3 result with revenues, gross profit and net income exceeding consensus expectations by 1%-10%, the analyst tells investors in a research note. ResMed’s key highlight was also the strong recovery in gross margin, which came through faster than anticipated, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Australian Stocks: ResMed (RMD) Shares Surge on Robust Q3 Results
- Resmed Inc (RMD) Q3 Earnings Cheat Sheet
- RBC says small surprise in Lilly’s trial could be viewed as positive for ResMed
- Inspire rises, ResMed slips as Street digests data from Lilly sleep apnea trials
- KeyBanc views Lilly’s SURMOUNT-OSA results as ‘a bit of a relief’ for Inspire
